KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Discontinued Operations (2022 - 2025)

Historic Cash from Discontinued Operations for TherapeuticsMD (TXMD) over the last 5 years, with Q3 2025 value amounting to $47000.0.

  • TherapeuticsMD's Cash from Discontinued Operations rose 14122.81% to $47000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28000.0, marking a year-over-year increase of 9915.51%. This contributed to the annual value of -$438000.0 for FY2024, which is 9825.22% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Cash from Discontinued Operations is $47000.0, which was up 14122.81% from -$57000.0 recorded in Q2 2025.
  • TherapeuticsMD's Cash from Discontinued Operations' 5-year high stood at $136.7 million during Q2 2022, with a 5-year trough of -$24.5 million in Q1 2023.
  • Its 4-year average for Cash from Discontinued Operations is $12.3 million, with a median of -$57000.0 in 2025.
  • The largest annual percentage gain for TherapeuticsMD's Cash from Discontinued Operations in the last 5 years was 14805.65% (2023), contrasted with its biggest fall of 11000.51% (2023).
  • Quarter analysis of 4 years shows TherapeuticsMD's Cash from Discontinued Operations stood at $92.8 million in 2022, then crashed by 103.11% to -$2.9 million in 2023, then surged by 99.83% to -$5000.0 in 2024, then surged by 1040.0% to $47000.0 in 2025.
  • Its Cash from Discontinued Operations stands at $47000.0 for Q3 2025, versus -$57000.0 for Q2 2025 and -$13000.0 for Q1 2025.